Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510057 | 0.98 | TDP1 (0.54) | TDP1FFAR4FFAR1AKR1B1CYP1A2 | |
| Naphthalene SCHEMBL1848110 | 0.93 | FFAR4 (0.50) | TDP1FFAR4FFAR1AKR1B1CYP1A2 | |
| SCHEMBL1820018 | 0.87 | FFAR4 (0.46) | TDP1FFAR4FFAR1AKR1B1CYP1A2 | |
| SCHEMBL4564283 | 0.86 | MTNR1A (0.54) | TDP1FFAR4FFAR1AKR1B1KDM4E | |
| SCHEMBL48684 | 0.86 | TDP1 (0.57) | TDP1FFAR4FFAR1AKR1B1CYP1A2 | |
| SCHEMBL7791197 | 0.85 | FFAR4 (0.48) | TDP1FFAR4FFAR1AKR1B1CYP1A2 | |
| SCHEMBL586305 | 0.85 | CYP1A2 (0.52) | TDP1AKR1B1CYP1A2CDYLMTNR1A | |
| SCHEMBL30307853 | 0.83 | TDP1 (0.67) | TDP1FFAR4FFAR1AKR1B1CYP1A2 | |
| SCHEMBL1218835 | 0.83 | TDP1 (0.67) | TDP1FFAR4FFAR1AKR1B1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11319694 | 0.82 | TDP1 (0.65) | TDP1FFAR4FFAR1AKR1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058294-B2 | Of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide; asthma and chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-11-15 | — | — | US | disclosed |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| EP-2364704-A1 | Combination of beta-adrenoceptor agonist and corticosteroid | AstraZeneca AB (SE) | 2011-09-14 | — | — | EP | disclosed |
| EP-2117542-B1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2323656-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2315589-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-04 | — | — | EP | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080249145-A1 | Salts 668 | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| EP-1957471-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS 2 ADRENOCEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096112-A1 | SALTS 668 | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1915354-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007027133-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249145-A1 | Salts 668 | DNPEP, SCN8A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TDP1 3343/4885FFAR4 2631/4885FFAR1 3028/4885 |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | TDP1 2812/4885FFAR4 1795/4885FFAR1 1540/4885 |
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TDP1 4472/4885FFAR4 271/4885FFAR1 253/4885 |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TDP1 4474/4885FFAR4 268/4885FFAR1 249/4885 |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TDP1 4400/4885FFAR4 232/4885FFAR1 248/4885 |
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | TDP1 1722/4885FFAR4 1166/4885FFAR1 412/4885 |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | TDP1 2812/4885FFAR4 1795/4885FFAR1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.